However, our finding that NOTCH1 could epigenetically restore STING pathway activity suggests that therapeutic NOTCH1 activation may be a strategy to convert typically cold immune-excluded or immune-desert SCLC tumors into “hot,” or immune-inflamed, tumors. This evidence concerns the gene NOTCH1 and small cell lung carcinoma.